Stockwatch. Pass the parcel
This article was originally published in Scrip
Executive Summary
Adolor’s re-acquisition this week of its rights to Entereg (alvimopan) from partner GlaxoSmithKline (scripintelligence.com, 15 Jun 2011) may provide investors with some useful clues, not just to the commercial potential for returned drugs, but also to the value of health economic analyses in pharmaceutical marketing and the value of the payments for re-acquired rights.